Elacestrant for Uterine Cancer

This trial tests a new treatment called elacestrant, a type of hormone therapy, for individuals with advanced uterine sarcomas that are estrogen receptor (ER)-positive. The trial aims to assess the treatment's effectiveness and safety. Participants take a daily dose and attend regular check-ins over several months. Ideal candidates have uterine sarcoma that cannot be surgically removed, is spreading, and shows strong signs of estrogen receptors in their tumors. As a Phase 2 trial, this research focuses on evaluating the treatment's effectiveness in an initial, smaller group of participants.

The trial requires that you stop taking strong CYP3A inducers or inhibitors at least 2 weeks before starting the study treatment. If you are on such medications, you will need to discuss alternatives with your doctor.

Research has shown that elacestrant is generally safe for people. Previous studies report mild side effects, such as nausea, as the most common. This treatment is a pill that targets estrogen receptors in cancer cells to inhibit their growth.

In a study on breast cancer, elacestrant was noted for its ease of use and manageable side effects compared to other treatments. The FDA has already approved it for certain types of estrogen receptor-positive cancers, indicating its safety.

Elacestrant is unique because it offers a novel approach to treating uterine cancer by acting as an oral selective estrogen receptor degrader (SERD). Unlike traditional treatments that often involve surgery, chemotherapy, or hormonal therapies like tamoxifen, Elacestrant directly targets and degrades the estrogen receptor, which is crucial for the growth of certain uterine cancers. Researchers are excited about Elacestrant because its oral administration and specific mechanism could offer a more convenient and targeted treatment option with potentially fewer side effects.

Research has shown that elacestrant, a drug targeting estrogen receptors, may effectively treat certain estrogen-driven cancers. In the EMERALD trial, elacestrant reduced the risk of cancer progression or death by 45% compared to standard treatments. After six months, 34.3% of patients on elacestrant experienced no cancer progression, while only 20.4% of those on standard care did. Although most research focuses on breast cancer, similar benefits are anticipated for uterine sarcomas due to shared hormone receptors. Elacestrant blocks and breaks down estrogen receptors, crucial for the growth of these cancers. Participants in this trial will receive a predetermined daily dose of elacestrant to assess its effectiveness in treating uterine cancer.³⁶⁷⁸⁹